Long-term safety of LUM-201 in children with growth hormone deficiency
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Hormones & metabolism clinical trials.
This study looks at the long-term safety of the medicine LUM-201, which helps children with growth hormone deficiency (a condition where the body doesn't make enough growth hormone, so growth is slower than normal). It is a follow-up for children who already completed the first year of the main study, to see if continuing the medicine is safe over a longer time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- This trial is for children who already finished the full 12 months in the earlier LUM-201 growth hormone deficiency study.
- You or your child must be able to visit the study center for the first day of the study.
- If sexually active, you must agree to use reliable birth control.
- You cannot join if you are pregnant.
- You cannot join if you are taking certain medications that could affect how the study drug works (like some heart or liver drugs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called LUM-201 for children who haven't grown enough because their bodies don't make enough growth hormone. It aims to help kids who haven't been treated before and are still at an early stage of puberty.
This trial tests a new growth hormone medicine (GB06) for children whose bodies don't make enough growth hormone naturally. The study will see if this treatment helps children grow taller over time.
This trial tests a new growth hormone injection (GB08) to see if it helps children with growth hormone deficiency grow taller. If your child is diagnosed with this condition and hasn't yet tried growth hormone treatment, they might benefit from participating.
This trial checks the long-term safety of LUM-201 in children who have idiopathic growth hormone deficiency and already completed an earlier LUM-201 study. If you previously took LUM-201 and are allowed to continue, the study may help your care team monitor ongoing effects over time.
This study tracks the safety of lonapegsomatropin in children being treated for growth hormone deficiency (GHD). It’s meant to check for side effects and make sure the medicine continues to be safe in real-world use.
This trial tests an oral medication called GS3-007a for children who have not yet reached puberty and have growth hormone deficiency. The goal is to see if it helps them grow taller.
Hear when a new Growth Hormone Deficiency (GHD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.